Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.591 USD -7.56% Intraday chart for Seelos Therapeutics, Inc. +20.59% -57.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected MT
Seelos Therapeutics' ALS treatment fails in mid-stage study RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose) CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9% MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024. CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024. CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024. CI
Sector Update: Health Care Stocks Gain Premarket Tuesday MT
Seelos Therapeutics Files $250 Million Mixed Shelf MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Top Premarket Decliners MT
Seelos Therapeutics Prices Common Stock Offering MT
Seelos Therapeutics Commences Common Stock Offering MT
Seelos Therapeutics, Inc. Announces the Selection of SLS-002 (intranasal Racemic Ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder CI
Top Decliners MT
Sector Update: Health Care Stocks Higher Friday Afternoon MT
Seelos Therapeutics Approves 1-for-30 Reverse Split of Common Stock; Shares Fall MT
Chart Seelos Therapeutics, Inc.
More charts
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
-
Number of Analysts
0
Last Close Price
0.591
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Seelos Therapeutics, Inc. - Nasdaq
  4. News Seelos Therapeutics, Inc.
  5. Seelos Therapeutics Gets License for iX Biopharma's Wafermine